Hartwig Huland Selected Research

Margins of Excision

1/2022	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.
1/2022	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
1/2021	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center.
6/2020	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
1/2020	Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
1/2020	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
12/2019	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer.
11/2019	NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.
10/2019	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
1/2019	A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hartwig Huland Research Topics

Disease

206	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 02/2002
122	Neoplasms (Cancer) 01/2022 - 02/2002
30	Margins of Excision 01/2022 - 04/2003
25	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2004
12	Lymphatic Metastasis 01/2021 - 11/2003
12	Carcinoma (Carcinomatosis) 01/2017 - 08/2002
10	Extranodal Extension 11/2017 - 02/2004
7	Urinary Bladder Neoplasms (Bladder Cancer) 05/2011 - 06/2004
5	Urinary Incontinence 11/2020 - 05/2011
4	Genomic Instability 01/2021 - 01/2020
4	7 Hereditary Prostate Cancer 07/2020 - 09/2017
4	Transitional Cell Carcinoma 09/2006 - 12/2004
4	Prostatic Diseases 05/2006 - 11/2002
3	Obesity 07/2018 - 08/2007
3	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 07/2008 - 12/2003
2	Erectile Dysfunction 01/2017 - 04/2007
2	Prostatic Intraepithelial Neoplasia 03/2010 - 12/2008
1	Circulating Neoplastic Cells 01/2021
1	Second Primary Neoplasms (Neoplasms, Second) 05/2020
1	Small Cell Carcinoma 09/2019
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Fistula 01/2018
1	Wounds and Injuries (Trauma) 01/2018

Drug/Important Bio-Agent (IBA)

69	Prostate-Specific Antigen (Semenogelase)IBA 12/2021 - 03/2002
25	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2004
18	Biomarkers (Surrogate Marker)IBA 07/2020 - 11/2003
10	AndrogensIBA 01/2022 - 11/2003
9	AntigensIBA 12/2021 - 06/2004
8	Biological ProductsIBA 01/2021 - 11/2003
8	DNA (Deoxyribonucleic Acid)IBA 08/2020 - 11/2004
7	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2020 - 12/2014
6	Hormones (Hormone)IBA 01/2021 - 02/2004
6	Tissue Kallikreins (Tissue Kallikrein)IBA 02/2007 - 02/2003
5	TensinsIBA 01/2020 - 12/2014
4	Serine Proteases (Serine Protease)IBA 01/2020 - 12/2014
4	Messenger RNA (mRNA)IBA 01/2020 - 03/2002
4	Capsules (Microcapsules)IBA 11/2019 - 06/2006
4	nuclear matrix protein 22IBA 09/2006 - 08/2002
3	Androgen Receptors (Androgen Receptor)IBA 12/2019 - 01/2019
3	isopropyl cyanoacrylateIBA 01/2015 - 08/2008
2	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 09/2004
2	Kallikreins (Kallikrein)IBA 01/2020 - 04/2009
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 11/2018
2	CEACAM1 ProteinIBA 01/2020 - 12/2004
2	SurvivinIBA 01/2020 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2019 - 06/2008
2	Dihydrotachysterol (AT 10)IBA 11/2017 - 07/2013
2	Histones (Histone)IBA 11/2015 - 06/2015
2	Indicators and Reagents (Reagents)IBA 07/2015 - 03/2002
2	Cell-Free Nucleic AcidsIBA 05/2011 - 09/2006
2	AntibodiesIBA 03/2010 - 06/2004
2	Protein Isoforms (Isoforms)IBA 04/2007 - 06/2004
2	Fluconazole (Zonal)FDA LinkGeneric 04/2007 - 07/2003
2	polyurethane-polypropylene composite (TMS 1)IBA 11/2005 - 11/2004
2	RNA (Ribonucleic Acid)IBA 09/2005 - 03/2002
2	Monoclonal AntibodiesIBA 06/2004 - 08/2002
1	AnoctaminsIBA 01/2021
1	gamma Catenin (Plakoglobin)IBA 01/2021
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2021
1	CateninsIBA 01/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 12/2020
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 11/2020
1	Heterogeneous Nuclear Ribonucleoprotein A1IBA 11/2020
1	WD repeat containing planar cell polarity effectorIBA 10/2020
1	Claudin-1IBA 09/2020
1	Abiraterone AcetateIBA 08/2020
1	Androgen Antagonists (Antiandrogens)IBA 08/2020
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 08/2020
1	indatuximab ravtansineIBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	CCCTC-Binding FactorIBA 01/2020
1	Proto-Oncogene Proteins c-etsIBA 11/2019
1	Protein Tyrosine PhosphatasesIBA 10/2019
1	Tyrosine (L-Tyrosine)FDA Link 10/2019
1	Amino Acids FDA Link 05/2019
1	Glycogen Synthase KinasesIBA 03/2019
1	taxaneIBA 03/2019
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 03/2019
1	CCAAT-Enhancer-Binding Protein-alphaIBA 01/2019
1	centromere protein FIBA 01/2018
1	Estrogens (Estrogen)FDA Link 01/2018
1	Proteoglycans (Proteoglycan)IBA 09/2017
1	BiglycanIBA 09/2017

Therapy/Procedure

141	Prostatectomy (Retropubic Prostatectomy) 10/2022 - 02/2002
25	Therapeutics 01/2022 - 11/2003
13	Lymph Node Excision (Lymph Node Dissection) 01/2019 - 02/2002
12	Radiotherapy 10/2022 - 11/2003
5	Castration 01/2021 - 04/2009
3	Adjuvant Radiotherapy 01/2022 - 03/2008
2	Catheters 01/2019 - 07/2014
2	Salvage Therapy 12/2017 - 11/2003
2	Lasers (Laser) 05/2014 - 09/2005
2	Chemoprevention 12/2007 - 10/2007
1	Combined Modality Therapy 01/2020
1	Length of Stay 01/2019
1	Transplantation 12/2018
1	Operative Surgical Procedures 01/2018
1	Enterostomy 01/2018
1	Aftercare (After-Treatment) 09/2017
1	Brachytherapy 05/2017